March 7, 2002
James B. Rothnie, Ph.D.
Senior Vice President, Chief Technology Officer
EMC Bets on AutoIS Offering
What is the history of your organization’s involvement in life sciences?
Rothnie: EMC has worked with pharmaceutical companies in their manufacturing, business and IT functions for more than a decade, with the top 10 pharmaceutical companies as EMC customers. Now, we’re leveraging our expertise to the drug discovery side of life sciences companies. With the initial mapping of the human genome, genomics, proteomics, bioinformatics, and clinical trials information are growing exponentially. EMC can help companies manage, share, and protect these tens of terabytes of information.
What is your vision for the development of the life sciences market?
Rothnie: Recent work in genomics and proteomics offers huge promise in improving our own personal lifestyles and health. I am very interested in driving technologies that will move us closer to individualized healthcare. EMC is well-positioned to help life sciences companies save significant time and money as new business models and drugs are introduced to the market. My goal is for EMC to continue as the information storage standard, helping life science companies develop new therapies.
What organizational assets have you developed to serve this community?
Rothnie: We’ve made a significant investment in the life sciences space by committing resources from engineering, sales, marketing, and other functions to focus on developing and delivering solutions that will help our customers and partners accelerate the drug discovery pipeline. EMC systems and software is the technology enabler to maximize drug pipeline efficiency by improving information sharing, research collaboration, and scalability.
What products and services does your company provide to the life sciences market?
Rothnie: Data integration is one of the key challenges our life sciences customers face, now that mapping of the human genome is moving towards the proteomics stage. Because life sciences companies are under such financial pressure to bring new drugs to market quickly, they are conducting their own drug discovery research, purchasing genomic research from other companies, and accessing public databases to solidify their competitive edge. All of this data arrives in different formats and is growing exponentially, therefore increasing the complexity of data management. We offer software that facilitates data access and movement through the infrastructure and are helping customers such as Gene Logic, Incyte Genomics, Vertex Pharmaceuticals, and Viaken Systems.
We recently introduced a major new technology in the storage market—Automated Information Storage, or AutoIS. EMC’s AutoIS software enables companies to automate and simplify labor-intensive information management processes—reducing the risk of human error and enabling businesses to do more with less. One of the main components of this strategy is data replication and recovery, what is known as business continuance. Most companies have been re-evaluating their business continuance solutions in recent months, with life sciences companies making sure their mission-critical research and clinical trials information is protected.
Return to main index page.